

An aggressive bone tumour: osteogenic osteomalacia

Authors: Carol Postlethwaite^A and Jesse Kumar^B




Fig 1. Tc99m bone scan.

A 58-year-old Caucasian man presented to his general practitioner with over 1 year of severe back pain and was discovered to have very low vitamin D3 levels (<10 nmol/l). Alkaline phosphatase was elevated at 160 U/l, calcium levels decreased to a low of 2.06 mmol/l and phosphate to 0.76 mmol/l. He was prescribed vitamin D supplements and levels began to normalise, but developed increasing pain in his right femur; an HDP Tc-99m bone scan revealed marked increased activity in the right proximal femur, indicating an aggressive



Fig 2. MRI scan of anterior thigh. MRI = magnetic resonance imaging.

osteoblastic process, in keeping with an osteosarcoma. Computed tomography (CT) and magnetic resonance imaging (MRI) scans confirmed a large tumour emanating from the right femoral head. The entire femur was resected and replaced with a titanium implant.

Oncogenic osteomalacia, also known as tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphate and vitamin D metabolism, caused by typically small endocrine tumours that secrete fibroblast growth factor 23 (FGF-23), a phosphatonin.¹ Typical features include hypophosphataemia due to renal phosphate wasting, inappropriately low to normal vitamin D levels and normal to elevated FGF-23. Patients suffer years of symptoms before diagnosis, leading to bone pain, fractures, depression and muscle weakness.

Reference

- 1 Masi L. The Phosphatonins: New Hormones the Cause of Numerous Congenital Bone Disorders. *Clin Cases Miner Bone Metab* 2010;7:174.

Authors: ^AST3, Department of Diabetes and Endocrinology, Maidstone Hospital, Kent, UK; ^Bconsultant, Department of Diabetes and Endocrinology, Maidstone Hospital, Kent

Address for correspondence: Dr C Postlethwaite, Acute Medical Unit (AMU), University College Hospital, 235 Euston Road, London NW1 2BU.
Email: carol.postlethwaite@nhs.net